Comparative Effectiveness in the Management of Irreversible Pulpitis
1 other identifier
interventional
138
1 country
1
Brief Summary
This project addresses a central question within the practice of dentistry: Is a pulpotomy procedure effective in the treatment of a tooth with symptomatic irreversible pulpitis and normal periapex? In addition, the project seeks to identify clinical and molecular biomarkers that are predictive of the success of pulpotomy.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable
Started Jun 2027
Longer than P75 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
June 4, 2021
CompletedFirst Posted
Study publicly available on registry
June 10, 2021
CompletedStudy Start
First participant enrolled
June 1, 2027
ExpectedPrimary Completion
Last participant's last visit for primary outcome
June 30, 2030
Study Completion
Last participant's last visit for all outcomes
December 31, 2031
February 17, 2026
February 1, 2026
3.1 years
June 4, 2021
February 12, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Percentage of patients with a successful outcome of pulpotomy versus RCT
A composite of clinical and radiographic findings and incidence of follow up procedures
From baseline through 2 years
Secondary Outcomes (2)
Determine prognostic validity of preoperative hyperalgesia in determining the outcome of pulpotomy
From baseline to two years
Determine prognostic validity of a set of pulpal inflammatory proteins in determining the outcome of pulpotomy
From baseline to 2 years
Study Arms (2)
Root canal treatment (RCT)
ACTIVE COMPARATORFor cases with this diagnosis RCT is the standard of care and will be done according to clinically approved protocols
Pulpotomy
EXPERIMENTALPulpotomy with tricalcium silicates has shown high clinical success in these cases. However, it is not known how this success compares to RCT under similar conditions and with an intent-to-treat study design, which will be employed here.
Interventions
This is the standard of care for this diagnosis
For cases with normal apical tissues, pulpotomy using tricalcium silicates has been shown to have high clinical success. Either partial or complete pulpotomy will be performed depending on the size of pulp exposure.
Eligibility Criteria
You may qualify if:
- Maxillary or mandibular first or second mature permanent molars with carious lesions or restorations (excluding crowns), with signs and symptoms of symptomatic irreversible pulpitis (defined as spontaneous pulpal pain and cold hyperalgesia \>30 seconds), and normal apical tissues.
- Tooth is responsive to cold and electrical pulp testing.
- Patients aged ≥12 years for first molars and ≥16 years for second molars.
You may not qualify if:
- Evidence of Pulp Necrosis or Apical Periodontitis, preoperatively or upon inspection of an exposure site
- Teeth that are badly broken down and/or are not restorable.
- Teeth with mechanical allodynia assessed by registering bite force that is at least 50N lower than the contralateral side.
- Teeth with radiographic evidence of internal, or external cervical, inflammatory or replacement root resorption, or with complete pulp canal obliteration.
- Radiographic evidence of PDL space wider than three times normal width
- Clinical evidence of swelling or sinus tract
- Periodontal pocket probing depth ≥5 mm in any site around the tooth.
- Clinical evidence of cracks connecting mesial and distal surfaces and/or extending in pulp chamber or associated with periodontal pockets ≥ 5 mm.
- History of taking centrally acting drugs (e.g., tricyclic antidepressants), which interfere with the release of pain mediators and/or modify pain experience, within the previous 6 months.
- Use of medications that affect the host response such as methotrexate, corticosteroids or cyclosporin.
- Patients on immunosuppressive agents, chronic corticosteroid use, autoimmune disease, or other immunocompromising diseases or medications.
- Patients who require IV sedation or general anesthesia for their dental treatment.
- Teeth with full coverage crowns.
- Teeth undergoing active orthodontic movement.
- Teeth that require elective RCTx to place a post for restorative purposes.
- +2 more criteria
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
School of Dentistry, University of Alabama at Birmingham
Birmingham, Alabama, 35233, United States
MeSH Terms
Interventions
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Ashraf Fouad, DDS
University of Alabama at Birmingham
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Professor and Chair
Study Record Dates
First Submitted
June 4, 2021
First Posted
June 10, 2021
Study Start (Estimated)
June 1, 2027
Primary Completion (Estimated)
June 30, 2030
Study Completion (Estimated)
December 31, 2031
Last Updated
February 17, 2026
Record last verified: 2026-02
Data Sharing
- IPD Sharing
- Will not share
To be determined